Sat Kartar Life

Sat Kartar Life delivered a strong Q4 FY26 with revenue crossing ₹200 croreCurrent reported value: ₹200 crore. No comparable prior figure is available in the source record. (up 23Current reported value: 23. No comparable prior figure is available in the source record.% YoY), EBITDA up 73%Current reported value: 73%. No comparable prior figure is available in the source record., and PAT up 74%Current reported value: 74%. No comparable prior figure is available in the source record.. Growth was driven by D2C product expansion, higher ticket sizes (now ₹3,250Current ₹3,250. Reported change: +150 YoY.), and the ramp-up of a new 30-bed hospital in Delhi. Management guided for product revenue of ₹300 croreCurrent reported value: ₹300 crore. No comparable prior figure is available in the source record. in FY27 and ₹500 croreCurrent reported value: ₹500 crore. No comparable prior figure is available in the source record. in FY28, supported by subsidiary Ajuni Life Sciences, US operations, and AI-driven efficiency gains. A strategic partnership with Gina aims to add 300 beds by FY27 and 1,000 by FY28, with a blended PAT margin target of 18-20% by H1 FY28. Key risk: hospital occupancy ramp-up may be slower than expected, given current utilization below 10Current reported value: 10. No comparable prior figure is available in the source record.% and pending insurance empanelment.